Previous Close | 82.50 |
Open | 82.60 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 900 |
Day's Range | 81.84 - 82.75 |
52 Week Range | 75.77 - 100.32 |
Volume | |
Avg. Volume | 6,072,480 |
Market Cap | 109.521B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | 29.18 |
EPS (TTM) | 2.82 |
Earnings Date | May 25, 2023 |
Forward Dividend & Yield | 2.76 (3.35%) |
Ex-Dividend Date | Jun 22, 2023 |
1y Target Est | 91.73 |
Nowhere is this trend more evident than in the recent parabolic growth of graphics, computing, and networking solutions company Nvidia (NASDAQ: NVDA). Thanks to its central role as a pillar of global AI architecture, Nvidia has seen its market cap swell to nearly $1 trillion in 2023.
Artificial intelligence (AI) could change the way we treat and prevent illnesses, which makes it a highly valuable opportunity for companies. In fact, the global AI healthcare market is set to reach more than $100 billion later this decade, a Markets and Markets report shows. Two perfect examples are biotech Moderna (NASDAQ: MRNA) and medical device giant Medtronic (NYSE: MDT).
History has shown that purchasing stocks in resilient companies that can weather market highs and lows is an effective long-term investment strategy. Ireland-based Medtronic (NYSE: MDT), a major player in the medical device industry, is one such company. For years, the company steadily increased its revenue and earnings, keeping its business stable.
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 44th annual Goldman Sachs global healthcare conference on Monday, June 12, 2023.
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Medtronic plc's ( NYSE:MDT ) periodic dividend will be increasing on the 14th of July to $0.69, with investors...
There was plenty of action in the company's shares in the wake of its divisive fourth-quarter results.
Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.
Joining me are Geoff Martha, Medtronic chairman and chief executive officer; and Karen Parkhill, Medtronic chief financial officer. Geoff and Karen will provide comments on the results of our fourth quarter and fiscal year 2023, which ended on April 28, 2023, and our outlook for fiscal year '24.
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Shares of the medical device maker Medtronic (NYSE: MDT) were down by 5% on heavy volume as of 10:53 a.m. ET Thursday. Although Medtronic topped Wall Street's consensus forecasts for the three-month period, investors appear to be reacting negatively to the company's financial guidance. Management blamed a stubbornly strong dollar and persistently high inflation for this softer-than-expected financial guidance.
Yahoo Finance Live discusses a drop in shares of Medtronic after the medical device maker issued a weaker than expected forecast.
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended April 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medtronic (MDT) delivered earnings and revenue surprises of 0.64% and 3.59%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Medtronic Plc on Thursday forecast annual profit below Wall Street estimates, as the medical device maker expects stronger dollar to continue dragging its sales down in international markets. Medtronic has warned of a delayed improvement in earnings this year as its costs continue to remain high despite restructuring efforts. It expects profit to be in the range of $5 per share to $5.10 per share for the fiscal year 2024, lower than analysts' estimates of $5.20 per share, according to Refinitiv IBES data.
(Reuters) -Medtronic Plc on Thursday forecast annual profit below Wall Street estimates, as a strong U.S. dollar and persistently high costs of raw goods weighed on the medical device maker's earnings, sending its shares down more than 4% in early trading. The company warned in February that rising raw material prices and high wages due to stubbornly high inflation would continue to impact its full-year profit. Medtronic forecast profit of $5 per share to $5.10 per share for the fiscal year 2024, below analysts' estimates of $5.20 per share, according to Refinitiv.
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd. (KOSDAQ: 294090), manufacturer of the EOPatch® device — a tubeless, wearable and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more i
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Medtronic (NYSE: MDT) is on a roll. Its shares have soared close to 15% year to date, easily outperforming the S&P 500. But is Medtronic a stock to consider buying right now? Here are the bull and bear cases for the medical device giant.
Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are perfect examples of this type of winning long-term investment. Medtronic sells devices worldwide related to diabetes, cardiovascular, neuroscience, and surgery. Thanks to its vast portfolio, Medtronic has increased earnings over time.
Medtronic is now designated as a "3+" company in the 50/50 Women on Boards Gender Diversity Directory™.
Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.
Investors who focus on long-term opportunities in the stock market look for well-established companies that are already profitable and have a track record of revenue growth. Two wildly different healthcare companies that both fit that description are Vertex Pharmaceuticals (NASDAQ: VRTX) and Medtronic (NYSE: MDT). Vertex, a biopharmaceutical company founded in 1989, has improved annual revenue by 636% over the past decade.
NORTHAMPTON, MA / ACCESSWIRE / May 18, 2023 / Medtronic During Asian American and Pacific Islander (AAPI) Heritage Month in May - and all year long - we come together to foster belonging among Asian and allied employees. Mani Prakash remembers ...
Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.